Jasper Therapeutics(US:JSPR) Newsfile·2025-11-12 00:25Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. regarding a federal securities class action lawsuit, with a lead plaintiff deadline set for November 18, 2025 [2][5]. Group 1: Legal Action and Investor Information - Investors who suffered losses in Jasper between November 30, 2023, and July 3, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights [1][2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. - The court-appointed lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [7]. Group 2: Allegations Against Jasper - The complaint alleges that Jasper and its executives violated federal securities laws by making false or misleading statements and failing to disclose critical information regarding their manufacturing processes and product suitability for clinical trials [5]. - Specific allegations include a lack of necessary controls for third-party manufacturers, which increased the risk of confounding study results and negatively impacted the regulatory and commercial prospects of Jasper's products, particularly briquilimab [5]. - Following a press release on July 7, 2025, regarding issues with a drug product lot, Jasper's stock price fell by $3.73 per share, or 55.1%, closing at $3.04 per share [6]. Group 3: Company Developments - The press release indicated that Jasper was halting development in asthma and SCID, and would implement cost-cutting measures, including potential restructuring, to extend its financial runway [6]. - Jasper's prior claims of having a strong balance sheet and cash runway extending through the third quarter of 2025 were contradicted by the announcement of these measures [6].